Tag Archives: Respiratory disease

Making Medicine Personal in Respiratory Health

Previously, we shared how we’re Making Medicine Personal for patients. We’re continuing the conversation by focusing on how we’re treating respiratory diseases.

Your health and that of your loved ones is one of the most important aspects of life. It’s also the most important aspect of our work. For more than 40 years, we’ve addressed respiratory challenges to improve millions of lives – and we’re not slowing down. We’re constantly developing new methods to advance quality of life while avoiding unnecessary costs and adding value to the overall healthcare system.

We understand that a one-size-fits-all approach doesn’t work in healthcare. Your cellular and molecular makeup is unique to you and you only. That’s why we’re focusing on tailored, individualized treatments to ensure that the right treatment is being delivered to the right patient.

Here’s how we’re doing this through innovation, patient assistance, and collaboration:

AZ_Respiratory-IG-860X1606

One of the main challenges of respiratory health is identifying the right dosage and treatment for each patient. With this in mind, we’re using new technologies, such as co-suspension technology, to enable consistent delivery of one or more different medicines in a single device, and we’re investigating biologics that have the potential to deliver uniquely targeted treatment for patients.

And that’s just the beginning. Access to proper treatment is the first step, but ensuring that patients maintain their treatments and adhere to doctor recommendations is equally important. Programs like Stay Connected Medication Adherence, AZCaRes™, and Health Journey Support allow us to be the patient’s coach and cheerleader.

“I’m so grateful for AstraZeneca’s savings cards. Your medicine has improved my asthma as the doctor believed it would.”

– AstraZeneca patient 

Hearing patients like the one above talk about how our programs have helped them brings meaning to our work. And that’s why we will never stop looking for ways to support and advocate for patients.

But we’re not in this alone. At AstraZeneca, we believe there is strength in numbers. Collaborative partnerships around the world enable us to pioneer research, technology, and awareness to improve patient outcomes. From working with the COPD Foundation to create one of the largest patient networks in existence, to collaborating with Adherium to explore the impact of technology on adherence, to annually partnering with the CHEST Foundation during World COPD Day and National COPD Awareness Month, our partnerships are key to our efforts.

At the end of the day, it’s our job to make sure our medicines bring value to you and the entire healthcare system. In future blog posts, we’ll share how we’re making medicine personal for patients living with cardiovascular and metabolic diseases as well as patients receiving cancer treatment. Stay tuned.

Resources Available for Chronic Obstructive Pulmonary Disease Patients

By Frank Trudo, MD, Medical Director

Breathing is a critical function.  But for millions of Americans with chronic obstructive pulmonary disease (COPD), the ability to breathe can be a struggle.

The third-leading cause of death in the US and a major cause of disability, COPD is one of the most prevalent respiratory diseases in the country. While 12 million Americans have been diagnosed with the disease, it’s estimated that another 12 million remain undiagnosed.

A progressive condition that usually starts in patients over the age of 40, COPD requires long-term treatment and care. In observance of COPD Awareness Month this November, AstraZeneca is demonstrating its commitment to ongoing COPD disease education, by making online resources, including information about the disease and treatment options, available for patients and health care providers.  Additional resources, including information on risk factors and tips to help manage COPD, can be found here.

Disease education is an important component of overall patient care. As a leader in respiratory disease research and treatments, AstraZeneca remains committed to supporting efforts to help the millions of Americans who are living with COPD.

You can learn more about AstraZeneca’s focus on respiratory and other key areas here.